摘要
新冠肺炎是一种新兴的疾病,是对全球社会的主要威胁。这种疾病的主要挑战是缺乏适当的或经过证实的药物治疗。用于治疗这种疾病的药物仅用于对症治疗。对其他冠状病毒,如SARS和MERS的研究表明,槲皮素有足够的潜力治疗covid-19。先前的研究表明,槲皮素通过阻断ACE2受体,以及降低SARS和MERS患者的白细胞介素-6水平,来减少病毒进入细胞的途径。因此,本综述的目的是从分子的角度仔细研究槲皮素作为一种治疗covid-19的药物的潜力。
关键词: 槲皮素、治疗性、covid-19、ACE2、SARS、MERS。
Current Molecular Medicine
Title:Quercetin and its Relative Therapeutic Potential Against COVID-19: A Retrospective Review and Prospective Overview
Volume: 21 Issue: 5
关键词: 槲皮素、治疗性、covid-19、ACE2、SARS、MERS。
摘要: COVID-19 is an emerging disease that is a major threat to the global community. The main challenge in this disease is the lack of proper or proven medication. The drugs used to treat this disease are only for symptomatic treatment. Studies of other coronaviruses, such as SARS and MERS, suggest that quercetin has sufficient potential to treat COVID-19. Previous studies have shown that quercetin reduces the entry of the virus into the cell by blocking the ACE2 receptor, as well as reducing the level of interleukin-6 in SARS and MERS patients. Therefore, the aim of this review was to scrutinize the potential of quercetin as a drug in the treatment of COVID-19 from a molecular perspective.
Export Options
About this article
Cite this article as:
Quercetin and its Relative Therapeutic Potential Against COVID-19: A Retrospective Review and Prospective Overview, Current Molecular Medicine 2021; 21 (5) . https://dx.doi.org/10.2174/1566524020999200918150630
DOI https://dx.doi.org/10.2174/1566524020999200918150630 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Cellular Mechanisms of Brain Injury and Cell Death
Current Pharmaceutical Design MicroRNAs-based Therapy: A Novel and Promising Strategy for Cancer Treatment
MicroRNA Peptimmunology: Immunogenic Peptides and Sequence Redundancy
Current Drug Discovery Technologies Gene Therapy in Cerebrovascular Diseases
Current Gene Therapy Enhancement of Immunoprotective Effect of CpG-ODN by Formulation with Polyphosphazenes Against E. coli Septicemia in Neonatal Chickens
Current Drug Delivery Role of AGEs in Diabetic Nephropathy
Current Pharmaceutical Design Matrix Gelatinases in Atherosclerosis and Diabetic Nephropathy: Progress and Challenges
Current Vascular Pharmacology DIMming Ovarian Cancer Growth
Current Drug Targets Influence of Usnic Acid and its Derivatives on the Activity of Mammalian Poly(ADP-ribose)polymerase 1 and DNA Polymerase β
Medicinal Chemistry Receptor Tyrosine Kinases as Therapeutic Targets in Malignant Glioma
Reviews on Recent Clinical Trials Determination of Propranolol and Naproxen in Urine by using Excitation-Emission Matrix Phosphorescence Coupled with Multivariate Calibration Algorithms
Current Pharmaceutical Analysis Extra Virgin Olive Oil and Cardiovascular Diseases: Benefits for Human Health
Endocrine, Metabolic & Immune Disorders - Drug Targets The Neurobiological Bases for Development of Pharmacological Treatments of Aggressive Disorders
Current Neuropharmacology The Evaluation and Management of Adult-Onset Henoch-Schonlein Purpura
Current Rheumatology Reviews Discovery of Novel Genes Mediating Glucose and Lipid Metabolisms
Current Protein & Peptide Science Nutrition as a Health Determinant in Elderly Patients
Current Medicinal Chemistry Connexins, Diabetes and the Metabolic Syndrome
Current Protein & Peptide Science Proprotein Convertase Subtilisin Kexin 9 (PCSK9) Inhibitors in the Treatment of Hypercholesterolemia and other Pathologies
Current Pharmaceutical Design Cancer/Testis Antigens Trigger Epithelial-Mesenchymal Transition and Genesis of Cancer Stem-Like Cells
Current Pharmaceutical Design Z-DNA Binding Proteins as Targets for Structure-Based Virtual Screening
Current Drug Targets